<?xml version="1.0" encoding="UTF-8"?>
<GaPExchange xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:noNamespaceSchemaLocation="./dbGaPEx2.1.5.xsd">

<MetaVariables>
	<Submitter/>
	<Method/>
</MetaVariables>
<MetaLinks/>

<Projects>
	<Project/>
</Projects>

<Studies>

<Study source="dbGaP" accession="phs000748.v2.p1" parentStudy="phs000748.v2.p1" createDate="2015-06-29" modDate="2015-07-15">

<Configuration>
	<Data_Provider><![CDATA[
		<table border="1">
		<tr><th>Title</th><th>Name</th><th>Institute</th></tr>
		<tr><td>Principal Investigator</td><td>Sagar Lonial, MD</td><td>Multiple Myeloma Research Foundation (MMRF), Norwalk, CT and Emory University, Atlanta, GA, USA</td></tr>
		<tr><td>Co-Principal Investigator</td><td>Fiona An, MD</td><td>Multiple Myeloma Research Foundation (MMRF), Norwalk, CT, USA</td></tr>
		</table>
	]]></Data_Provider>
	<StudyNameEntrez>Multiple Myeloma CoMMpass Study</StudyNameEntrez>
	<StudyNameReportPage>Relating Clinical Outcomes in Multiple Myeloma to Personal Assessment of Genetic Profile</StudyNameReportPage>
	<StudyTypes>
		<StudyType>Longitudinal</StudyType>
	</StudyTypes>
	<Description><![CDATA[
<p>The Multiple Myeloma Research Foundation (MMRF) CoMMpass (Relating <u>C</u>linical <u>O</u>utcomes in <u>MM</u> to <u>P</u>ersonal <u>Ass</u>essment of Genetic Profile) trial (NCT01454297) is a longitudinal observation study of 1000 newly diagnosed myeloma patients receiving various standard approved treatments that aim at collecting tissue samples, genetic information, Quality of Life (QoL) and various disease and clinical outcomes over 10 years.</p>]]>
	</Description>
	<StudyInEx><![CDATA[
<p>The treatment regimen selected for the patient is at the discretion of the treating investigator. However, the initial regimen must contain an FDA-approved IMiD&#174; and/or a proteasome inhibitor. Other than this requirement, the study does not dictate dose, schedule or any other specific treatment requirement.</p> <p><b>Inclusion Criteria:</b> <ul> <li>Patient is at least 18 years old.</li> <li>Patient has been diagnosed with symptomatic MM with measurable disease that includes at least one of the following: <ul> <li>Serum M protein &#8805; 1g/dl Urine M protein &#8805; 200 mg/24 hrs Involved free light chain level &#8805; 10 mg/dl and an abnormal serum free light chain ratio (&lt; 0.26 or &gt; 1.65).</li> <li>The patient is a candidate for systemic therapy that includes an IMiD&#174; (e.g., lenalidomide, pomalidomide, thalidomide) and/or proteasome inhibitor (e.g., bortezomib, carfilzomib) as part of the initial regimen.</li> <li>No more than 30 days from baseline bone marrow evaluation as per this protocol to initiation of first-line therapy.</li> <li>Patient has read, understood and signed informed consent.</li> </ul> </li> </ul> </p> <p><b>Exclusion Criteria:</b> <ul> <li>Patient is already receiving systemic therapy for MM (a single dose of bisphosphonates and up to 100 mg total dose of dexamethasone or equivalent corticosteroids are permitted prior to registration on study).</li> <li>Patient had another malignancy within the last 5 years (except for basal or squamous cell carcinoma, or in situ cancer of the cervix).</li> <li>Patient is enrolled in a blinded clinical trial for the first-line treatment of multiple myeloma. Patients may be enrolled in subsequent clinical trials as long as continued access to data and tissue, as per this protocol, is not prohibited.</li> </ul> </p>]]>
	</StudyInEx>
	<StudyProjects>
		<Project/>
	</StudyProjects>
	<Publications>
		<Publication>
			<Journal authors="Keats JJ, Craig DW, Liang W, Venkata Y, Kurdoglu A, Aldrich J, Auclair D, Allen K, Harrison B, Jewell S, Kidd PG, Correll M, Jagannath S, Siegel DS, Vij R, Orloff G, Zimmerman TM, MMRF CoMMpass Network, Capone W, Carpten J, Lonial S." title="Interim Analysis Of The MMRF CoMMpass Trial, a Longitudinal Study In Multiple Myeloma Relating Clinical Outcomes To Genomic and Immunophenotypic Profiles" journal="Blood 2013; 122:532"/>
		</Publication>
	</Publications>
	<Diseases>
		<Disease vocab_source="MESH" vocab_term="Multiple Myeloma"/>
		<Disease vocab_source="MESH" vocab_term="Neoplasms, Plasma Cell"/>
	</Diseases>
	<Attributions>
		<Header title="Principal Investigator">
			<AttName>Sagar Lonial, MD</AttName>
			<Institution>Multiple Myeloma Research Foundation (MMRF), Norwalk, CT and Emory University, Atlanta, GA, USA</Institution>
		</Header>
		<Header title="Co-Principal Investigator">
			<AttName>Fiona An, MD</AttName>
			<Institution>Multiple Myeloma Research Foundation (MMRF), Norwalk, CT, USA</Institution>
		</Header>
	</Attributions>
	<DisplayPublicSummary>yes</DisplayPublicSummary>
	<StudyURLs>
		<Url name="MMRF" url="http://www.themmrf.org/research-programs/commpass-study/"/>
	</StudyURLs>
	<StudyHistory><![CDATA[
<p>The study was initiated in 2011.</p>]]>
	</StudyHistory>
	<ConsentGroups>
		<ConsentGroup groupNum="1" shortName="GRU-MDS" longName="General Research Use (MDS)"/>
		<ConsentGroup groupNum="2" shortName="DS-MCRD-MDS" longName="Disease-Specific (Myeloma and other cancer-related disorders, MDS)"/>
	</ConsentGroups>
</Configuration>

  <AuthorizedAccess>
    <DacInfo ssDacId="0">
      <DacName>NCI</DacName>
      <DacFullName>NCI</DacFullName>
      <DacEmail>0</DacEmail>
      <DacPhone></DacPhone>
      <DacUrl></DacUrl>
    </DacInfo>
    <Policy Policy_ID="phs000748.v2.p1_policy" ref_ssDacId="0">
      <DisplayResearchStatement>yes</DisplayResearchStatement>
      <DisplayPublicSummary>yes</DisplayPublicSummary>
      <EmbargoLength>0</EmbargoLength>
      <YearsUntilRenewal>1</YearsUntilRenewal>
      <WeeksCancelRequest>8</WeeksCancelRequest>
      <PdfSupplementReqired>no</PdfSupplementReqired>
      <AcknowledgementText>
        <para>
          http://dbgap.ncbi.nlm.nih.gov/aa/wga.cgi?page=DUC&amp;view_pdf&amp;stacc=phs000748.v2.p1
        </para>
      </AcknowledgementText>
      <DocumentSet>
        <DataUseCertificate Label="Data Use Certificate" FilePath="https://dbgap.ncbi.nlm.nih.gov/aa/wga.cgi?page=DUC&amp;view_pdf&amp;stacc=phs000748.v2.p1" FileName=""/>
      </DocumentSet>
    </Policy>
    <ConsentGroups>
      <ParticipantSet groupNum-REF="1">
        <ConsentName>General Research Use (MDS)</ConsentName>
        <ConsentAbbrev>GRU-MDS</ConsentAbbrev>
        <UseLimitation>Use of the data is limited only by the terms of the model Data Use Certification.
Use of the data includes methods development research (e.g., development of software or algorithms).</UseLimitation>
        <IrbRequired>No</IrbRequired>
      </ParticipantSet>
      <ParticipantSet groupNum-REF="2">
        <ConsentName>Disease-Specific (Myeloma and other cancer-related disorders, MDS)</ConsentName>
        <ConsentAbbrev>DS-MCRD-MDS</ConsentAbbrev>
        <UseLimitation>Use of the data must be related to Myeloma and other cancer-related disorders.
Use of the data includes methods development research (e.g., development of software or algorithms).</UseLimitation>
        <IrbRequired>No</IrbRequired>
      </ParticipantSet>
      <ParticipantSet groupNum-REF="999">
        <ConsentName>Exchange Area</ConsentName>
        <ConsentAbbrev>EA</ConsentAbbrev>
        <UseLimitation>Pre-release exchange area for use by study investigators only.</UseLimitation>
        <IrbRequired>No</IrbRequired>
      </ParticipantSet>
    </ConsentGroups>
  </AuthorizedAccess>


</Study>

</Studies>

</GaPExchange>
